Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod vs Dimethyl Fumarate in RRMS
NCT03345940Phase 4Terminated
- Sponsor
- Carlo Besta Neurological Institute
- Start
- Apr 2017
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fingolimod, dimethyl fumarate in multiple sclerosis (MS), sponsored by Carlo Besta Neurological Institute. Started Apr 2017; status: terminated.
02
Drugs
fingolimoddimethyl fumarate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03345940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03345940.